KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xylem (XYL) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Xylem (XYL) over the last 16 years, with Q3 2025 value amounting to $1.2 billion.

  • Xylem's Cash & Equivalents rose 2042.47% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 2042.47%. This contributed to the annual value of $1.1 billion for FY2024, which is 1000.98% up from last year.
  • According to the latest figures from Q3 2025, Xylem's Cash & Equivalents is $1.2 billion, which was up 2042.47% from $1.2 billion recorded in Q2 2025.
  • Xylem's Cash & Equivalents' 5-year high stood at $1.8 billion during Q2 2021, with a 5-year trough of $705.0 million in Q3 2023.
  • Moreover, its 5-year median value for Cash & Equivalents was $1.1 billion (2022), whereas its average is $1.1 billion.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 12841.68% in 2021, then crashed by 4055.65% in 2023.
  • Over the past 5 years, Xylem's Cash & Equivalents (Quarter) stood at $1.3 billion in 2021, then tumbled by 30.02% to $944.0 million in 2022, then increased by 7.94% to $1.0 billion in 2023, then rose by 10.01% to $1.1 billion in 2024, then rose by 6.24% to $1.2 billion in 2025.
  • Its Cash & Equivalents was $1.2 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.1 billion in Q1 2025.